LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc.

Medical/Dental Instruments

Health Care

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

IPO Year: 2021

Exchange: NASDAQ

Website: luciddx.com

Peers

$PAVM

Recent Analyst Ratings for Lucid Diagnostics Inc.

Date	Price Target	Rating	Analyst
12/27/2021	$16.00	Buy	Ascendiant Capital
12/15/2021	$17.00 → $13.00	Buy	Needham
11/8/2021	$18.00	Buy	Canaccord Genuity
11/8/2021	$14.00	Buy	BTIG Research
11/8/2021	$21.00	Overweight	Cantor Fitzgerald
11/8/2021	$17.00	Buy	Needham

See more ratings

Lucid Diagnostics Inc.

Peers

Recent Analyst Ratings for Lucid Diagnostics Inc.

Lucid Diagnostics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

President and COO O'Neil Shaun was granted 300,000 shares, increasing direct ownership by 57% to 826,763 units (SEC Form 4)

Chief Executive Officer Aklog Lishan was granted 300,000 shares, increasing direct ownership by 26% to 1,466,627 units (SEC Form 4)

Director Sokolov Jacque J was granted 112,800 shares, increasing direct ownership by 133% to 197,460 units (SEC Form 4)

Director Lapidus Stanley was granted 112,800 shares, increasing direct ownership by 111% to 214,392 units (SEC Form 4)

Director Matheis Dennis was granted 112,800 shares, increasing direct ownership by 226% to 162,725 units (SEC Form 4)

Director Cox James L was granted 112,800 shares, increasing direct ownership by 67% to 282,120 units (SEC Form 4)

Chief Financial Officer Mcgrath Dennis M was granted 300,000 shares, increasing direct ownership by 29% to 1,343,569 units (SEC Form 4)

General Counsel and Secretary Gordon Michael Adam was granted 300,000 shares, increasing direct ownership by 75% to 700,000 units (SEC Form 4)